Kansas is currently home to 890 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Wichita, Kansas City, Overland Park and Topeka. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222
Recruiting
Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all patients exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion to assess the risk of delayed adverse events (AEs), monitor for replication competent lentivirus (RCL) and assess long-term efficacy, including vector per... Read More
Gender:
ALL
Ages:
Between 0 years and 100 years
Trial Updated:
08/15/2025
Locations: University of Kansas Cancer Center SC, Westwood, Kansas
Conditions: Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Register for Updates
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686
Recruiting
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Kansas University Medical Center, Westwood, Kansas
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
Register for Updates
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of K-645 in the Treatment of Multiple Migraine Attacks
NCT07116499
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/14/2025
Locations: Collective Medical Research, Overland Park, Kansas
Conditions: Acute Migraine
Register for Updates
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
NCT07024641
Recruiting
The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Grifols Investigative Site, Lenexa, Kansas
Conditions: Hepatitis B Virus Infection
Register for Updates
A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease
NCT07011771
Recruiting
The goal of this clinical trial is to learn about the safety of CAP-003 gene therapy in adults with GBA1 associated Parkinson's Disease. It will also provide information about whether CAP-003 demonstrates efficacy in these adults. Participants will have a single intravenous infusion of CAP-003 and visit the clinic regularly for 2 years for checkups and tests.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
08/14/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: GBA1 Parkinson Disease
Register for Updates
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
NCT06869785
Recruiting
This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/14/2025
Locations: Univ of Kansas Hosp and Med Ctr, Kansas City, Kansas
Conditions: Relapsing Multiple Sclerosis (RMS)
Register for Updates
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579
Recruiting
The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2025
Locations: Clinical Study Site, Kansas City, Kansas
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723
Recruiting
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Research Site, Hutchinson, Kansas
Conditions: Chronic Kidney Disease and Hypertension
Register for Updates
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347
Recruiting
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Cotton O'Neil Cancer Center ( Site 0108), Topeka, Kansas
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772
Recruiting
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE). The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2025
Locations: Hutchinson Clinic- Site Number : 8400020, Hutchinson, Kansas
Conditions: Coeliac Disease, Celiac Disease
Register for Updates
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
NCT06552416
Recruiting
This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or \Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/14/2025
Locations: KU Cancer Center, KAnsas city, Kansas
Conditions: Acute Myeloid Leukemia, in Relapse, MDS
Register for Updates
A Study in Patients With Mixed Dyslipidemia
NCT06497127
Recruiting
A Phase 2 in Patients With Mixed Dyslipidemia
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2025
Locations: Alliance for Multispecialty Research, LLC, Newton, Kansas
Conditions: Mixed Dyslipidemia
Register for Updates